Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Still Plans Big Cost Savings This Year From Schering-Plough Deal

Executive Summary

In his first public appearance since completing the acquisition last November of Schering-Plough, Merck chief executive Richard Clark told an investor conference that roughly half of the projected savings from the merger can be realized this year

You may also be interested in...

FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming

SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.

Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive

However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts